Pro CLB Global Limited held its 32nd Annual General Meeting on September 30, 2026, through video conferencing and other audio-visual means. The meeting was chaired by Director Het Kalpeshkumar Shah, who confirmed the requisite quorum was present.

The company adopted the audited financial statements for the financial year ended March 31, 2026. Shareholders also approved several key appointments, including the reappointment of Het Kalpeshkumar Shah as a Non-Executive Director retiring by rotation. Additionally, M/s. Shweta Jain & Co LLP was appointed as Statutory Auditors for a term extending until the conclusion of the 37th AGM.

Governance and Board Changes

The meeting addressed significant governance updates. Satish Papnai was regularized from his role as an additional director to an Independent Director. This move aligns with regulatory requirements for board composition. Furthermore, M/s Rohit Bhatia & Associates were appointed as Secretarial Auditors for a term of five consecutive financial years.

Voting on these resolutions was conducted electronically via CDSL. The e-voting period commenced on September 27, 2026, and concluded on September 29, 2026. Members who did not vote during this window could cast their votes during the AGM itself, up to 15 minutes after the meeting's conclusion.

Resolution Highlights

The following ordinary and special resolutions were passed with the requisite majority:

1. Adoption of audited financial statements and reports for FY26.
2. Reappointment of Het Kalpeshkumar Shah as Non-Executive Director.
3. Appointment of M/s. Shweta Jain & Co LLP as Statutory Auditors.
4. Regularization of Satish Papnai as an Independent Director.
5. Appointment of M/s Rohit Bhatia & Associates as Secretarial Auditors.

The meeting concluded at 4:25 pm with a vote of thanks. Results of the voting are to be announced within 48 hours and will be available on the company website and BSE India.

Pro CLB Global approved the allotment of 1,09,20,255 convertible warrants to 130 non-promoter investors on September 16, 2026. The preferential issue was priced at ₹31.96 per warrant, with an initial collection of ₹7.99 per warrant representing 25% of the total consideration.

The Board of Directors sanctioned the allotment during a meeting held on September 16, 2026, from 5:00 pm to 5:30 pm. The issuance complies with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Allotment Details

The warrants entitle holders to subscribe to one equity share per warrant upon payment of the remaining 75% of the issue price. Holders must exercise this right within 18 months from the date of allotment. Failure to exercise the warrants within this period will result in their lapse, and the amounts paid will be forfeited by the company.

Ten applicants were not allotted warrants due to non-receipt of the required 25% upfront payment. These include Chirayu Aggarwal, Geeta Sanjay Arora, and Siroya Enterprise.

Key Investors

The allotment was distributed among a broad base of retail and high-net-worth individuals, along with a few corporate entities. Mideast Healthcare Pvt Ltd received the largest single allotment of 700,000 warrants. Rajnikant Chandulal Shukla HUF was allotted 650,000 warrants, followed by Neeta Mandevia with 531,915 warrants.

What the Numbers Show

The wide dispersion of allottees, with 130 distinct recipients and no single investor holding more than 4.37% of the post-allotment stake, indicates a strategy to broaden the shareholder base rather than consolidate control. The inclusion of multiple HUFs and individual family members suggests participation from the company's existing promoter or management circle, structured as non-promoter investments.